Business Context and Reporting Period
West Pharmaceutical Services, Inc. filed an unaudited Form 10-Q for the three months ended March 31, 2016. The company develops and manufactures pharmaceutical packaging, delivery systems, components, and contract-manufactured assemblies. Beginning in 2016, reporting changed to Proprietary Products and Contract-Manufactured Products, with prior-period segment information retroactively adjusted.
Key Financial Metrics
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Net sales | $362.1 million | $335.9 million | +7.8%; +10.5% excluding currency |
| Gross profit | $123.3 million | $109.7 million | +12.4% |
| Gross margin | 34.0% | 32.7% | +1.3 percentage points |
| Operating profit | $30.0 million | $47.8 million | -37.2% |
| Operating margin | 8.3% | 14.2% | -5.9 percentage points |
| Adjusted operating profit | $55.6 million | $47.8 million | +16.3% |
| Adjusted operating margin | 15.4% | 14.2% | +1.2 percentage points |
| Net income | $22.1 million | $32.9 million | -32.8% |
| Diluted EPS | $0.30 | $0.45 | -33.3% |
| Operating cash flow | $3.0 million | $(1.9) million | +$4.9 million |
| Capital expenditures | $39.0 million | $30.4 million | +$8.6 million |
Proprietary Products sales increased 9.6% as reported and 13.0% excluding currency, driven by Daikyo, Daikyo RSV, Westar, and FluroTec-coated products. Contract-Manufactured Products sales increased 1.2% as reported. Proprietary Products operating profit was $61.9 million, while Contract-Manufactured Products operating profit was $7.0 million.
Financial Condition, Debt, and Liquidity
- Cash and cash equivalents were $178.1 million at March 31, 2016, down from $274.6 million at December 31, 2015.
- Working capital was $389.6 million, compared with $359.4 million at year-end.
- The debt note reports total debt of $233.0 million, including $229.5 million of long-term debt net of issuance costs. The liquidity table reports total debt of $232.0 million.
- The company repaid $68.0 million of debt, including the maturity of its $66.8 million Euro note B.
- The $300.0 million revolving credit facility had $28.2 million drawn and $268.8 million of available borrowing capacity after letters of credit.
- Management stated that cash, operating cash generation, and revolver availability should meet foreseeable liquidity needs. The company was in compliance with its debt covenants.
Material Changes and Unusual Items
- Restructuring and related charges totaled $22.9 million, including $7.9 million of severance and $15.0 million of non-cash asset write-downs. Management expects total charges of $25.0 million to $28.0 million, with remaining charges expected during the rest of 2016 and in 2017.
- The restructuring reduced Q1 2016 net income by approximately $15.0 million and diluted EPS by $0.20, after tax.
- A $2.7 million charge resulted from the Venezuelan Bolivar devaluation, reducing net income by approximately $2.5 million and diluted EPS by $0.03. Further devaluations could produce a pre-tax charge of up to $5.7 million.
- Foreign currency movements reduced reported sales by $9.1 million, gross profit by $3.3 million, operating profit by $2.4 million, net income by $1.7 million, and diluted EPS by $0.02.
- Net interest expense declined 40.5% to $2.2 million, primarily because of lower debt and higher capitalized interest associated with capital projects, including the Waterford, Ireland facility.
- The company repurchased 142,800 shares for $9.1 million under a program authorizing up to 700,000 shares; 557,200 shares remained available at March 31, 2016.
Outlook, Commentary, and Risks
The filing does not provide a specific full-year revenue or earnings guidance range. Management emphasized growth in high-value proprietary products, continued investment in advanced delivery systems and manufacturing capacity, and expected benefits from product mix and production efficiencies.
Key risks include customer demand and product-launch timing, regulatory approvals for customer products incorporating West systems, competition and pricing pressure, supply-chain interruptions, dependence on critical suppliers and partners including Daikyo, petroleum-based raw-material costs, foreign-exchange volatility, Venezuela-related developments, availability of skilled labor, and global healthcare legislation. The company also uses derivatives to manage interest-rate, currency, and commodity-price exposures.
Management reported no material changes to previously disclosed commitments, contingencies, market-risk exposures, or risk factors. There were no legal proceedings reported as material, no material changes in internal control over financial reporting, and no off-balance-sheet financing arrangements other than ordinary-course operating leases, purchase obligations, and letters of credit.
Investor Verification Points
- Verify the remaining timing and cash impact of the $25.0 million to $28.0 million restructuring plan.
- Assess whether Proprietary Products growth and improved adjusted margins offset contract-manufacturing softness and currency headwinds.
- Monitor cash conversion, capital expenditures, the Waterford facility, and the decline in cash following debt repayment and share repurchases.
- Reconcile the $232.0 million total debt shown in the liquidity table with the $233.0 million debt amount shown in the debt note.
- Evaluate exposure to additional Venezuelan currency devaluation, foreign-exchange movements, raw-material prices, and customer regulatory or commercialization delays.
- Confirm the effect of the segment-reporting change and the use of non-GAAP adjusted operating profit and constant-currency measures.